A One-Year Trial of Lamivudine for Chronic Hepatitis B

doi:10.1056/NEJM199807093390201

Volume 339:61-68		July 9, 1998		Number 2

A One-Year Trial of Lamivudine for Chronic Hepatitis B

Ching-Lung Lai, M.D., Rong-Nan Chien, M.D., Nancy W.Y. Leung, M.D., Ting-Tsung Chang, M.D., Richard Guan, M.D., Dar-In Tai, M.D., Keng-Yeen Ng, M.D., Pui-Chee Wu, M.D., Julie C. Dent, Ph.D., Judy Barber, M.Sc., Sally L. Stephenson, Ph.D., D. Fraser Gray, Ph.D., for The Asia Hepatitis Lamivudine Study Group

Full Text

PDF

Editorial
by Omata, M.

Letters

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

ABSTRACT

Background and Methods In preliminary trials, lamivudine, anoral nucleoside analogue, has shown promise for the treatmentof chronic hepatitis B. We conducted a one-year, double-blindtrial of lamivudine in 358 Chinese patients with chronic hepatitisB. The patients were randomly assigned to receive 25 mg of lamivudine(142 patients), 100 mg of lamivudine (143), or placebo (73)orally once daily. The patients underwent liver biopsies beforeentering the study and after completing the assigned treatmentregimen. The primary end point was a reduction of at least twopoints in the Knodell necroinflammatory score.

Results Hepatic necroinflammatory activity improved by two pointsor more in 56 percent of the patients receiving 100 mg of lamivudine,49 percent of those receiving 25 mg of lamivudine, and 25 percentof those receiving placebo (P<0.001 and P=0.001, respectively,for the comparisons of lamivudine treatment with placebo). Necroinflammatoryactivity worsened in 7 percent of the patients receiving 100mg of lamivudine, 8 percent of those receiving 25 mg, and 26percent of those receiving placebo. The 100-mg dose of lamivudinewas associated with a reduced progression of fibrosis (P=0.01for the comparison with placebo) and with the highest rate ofhepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg,development of antibody to HBeAg, and undetectable HBV DNA)(16 percent), the greatest suppression of HBV DNA (98 percentreduction at week 52 as compared with the base-line value),and the highest rate of sustained normalization of alanine aminotransferaselevels (72 percent). Ninety-six percent of the patients completedthe study. The incidence of adverse events was similar in allgroups, and there were few serious events.

Conclusions In a one-year study, lamivudine was associated withsubstantial histologic improvement in many patients with chronichepatitis B. A daily dose of 100 mg was more effective thana daily dose of 25 mg.

Source Information

From the Departments of Medicine (C.-L.L.) and Pathology (P.-C.W.), Queen Mary Hospital, Hong Kong, China; the Liver Unit, Chang Gung Memorial Hospital, Taipei, Taiwan (R.-N.C.); the Department of Medicine, Prince of Wales Hospital, Hong Kong, China (N.W.Y.L.); the Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan (T.-T.C.); the Department of Medicine, National University Hospital, Singapore (R.G.); the Liver Unit, Chang Gung Memorial Hospital, Kaohsiung Hsein, Taiwan (D.-I.T.); the Department of Gastroenterology, Singapore General Hospital, Singapore (K.-Y.N.); the Medical Affairs Department, Glaxo Wellcome China, Hong Kong (J.C.D.); and the Departments of European Clinical Statistics (J.B.) and Infectious Diseases and Rheumatology (S.L.S., D.F.G.), Glaxo Wellcome Research and Development, Greenford, United Kingdom.

Address reprint requests to Dr. Lai at the Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China.

Full Text of this Article

Related Letters:

Lamivudine for Chronic Hepatitis B
Bernasconi E., Battegay M., Lai C.-L., Chien R.-N., Leung N. W.Y.
Extract | Full Text
N Engl J Med 1998; 339:1786, Dec 10, 1998. Correspondence

This article has been cited by other articles:

Soriano, V., Perelson, A. S., Zoulim, F. (2008). Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?. J Antimicrob Chemother 62: 1-4 [Abstract] [Full Text]
Cooksley, H., Chokshi, S., Maayan, Y., Wedemeyer, H., Andreone, P., Gilson, R., Warnes, T., Paganin, S., Zoulim, F., Frederick, D., Neumann, A. U., Brosgart, C. L., Naoumov, N. V. (2008). Hepatitis B Virus e Antigen Loss during Adefovir Dipivoxil Therapy Is Associated with Enhanced Virus-Specific CD4+ T-Cell Reactivity. Antimicrob. Agents Chemother. 52: 312-320 [Abstract] [Full Text]
Dusheiko, G, Antonakopoulos, N (2008). Current treatment of hepatitis B. Gut 57: 105-124 [Full Text]
Chan, H. L.Y., Heathcote, E. J., Marcellin, P., Lai, C.-L., Cho, M., Moon, Y. M., Chao, Y.-C., Myers, R. P., Minuk, G. Y., Jeffers, L., Sievert, W., Bzowej, N., Harb, G., Kaiser, R., Qiao, X.-J., Brown, N. A., and the 018 Study Group, (2007). Treatment of Hepatitis B e Antigen Positive Chronic Hepatitis with Telbivudine or Adefovir: A Randomized Trial. ANN INTERN MED 147: 745-754 [Abstract] [Full Text]
Gehring, A. J., Sun, D., Kennedy, P. T. F., Nolte-'t Hoen, E., Lim, S. G., Wasser, S., Selden, C., Maini, M. K., Davis, D. M., Nassal, M., Bertoletti, A. (2007). The Level of Viral Antigen Presented by Hepatocytes Influences CD8 T-Cell Function. J. Virol. 81: 2940-2949 [Abstract] [Full Text]
Saikia, N., Talukdar, R., Mazumder, S., Khanna, S., Tandon, R. (2007). Management of patients with HBeAg-negative chronic hepatitis B. Postgrad. Med. J. 83: 32-39 [Abstract] [Full Text]
Shi, M., Wang, R. S., Zhang, H., Zhu, Y. F., Han, B., Zhang, Y., Jin, L. J., Yang, Z.-J., Xu, Y. P. (2006). Sequential treatment with lamivudine and interferon-{alpha} monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother 58: 1031-1035 [Abstract] [Full Text]
Yatsuji, H., Noguchi, C., Hiraga, N., Mori, N., Tsuge, M., Imamura, M., Takahashi, S., Iwao, E., Fujimoto, Y., Ochi, H., Abe, H., Maekawa, T., Tateno, C., Yoshizato, K., Suzuki, F., Kumada, H., Chayama, K. (2006). Emergence of a Novel Lamivudine-Resistant Hepatitis B Virus Variant with a Substitution Outside the YMDD Motif. Antimicrob. Agents Chemother. 50: 3867-3874 [Abstract] [Full Text]
Rincon, D., Ripoll, C., Catalina, M. V., Salcedo, M., Banares, R. (2006). Does interferon improve portal hypertension?. J Antimicrob Chemother 58: 7-12 [Abstract] [Full Text]
Osborn, M. K., Lok, A. S. F. (2006). Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother 57: 1030-1034 [Abstract] [Full Text]
Lim, S. G., Krastev, Z., Ng, T. M., Mechkov, G., Kotzev, I. A., Chan, S., Mondou, E., Snow, A., Sorbel, J., Rousseau, F., for the FTCB-204 Study Group, (2006). Randomized, Double-Blind Study of Emtricitabine (FTC) plus Clevudine versus FTC Alone in Treatment of Chronic Hepatitis B.. Antimicrob. Agents Chemother. 50: 1642-1648 [Abstract] [Full Text]
Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., Cross, A., DeHertogh, D., Wilber, R., Colonno, R., Apelian, D., the BEHoLD AI463022 Study Group, (2006). A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. NEJM 354: 1001-1010 [Abstract] [Full Text]
Pallier, C., Castera, L., Soulier, A., Hezode, C., Nordmann, P., Dhumeaux, D., Pawlotsky, J.-M. (2006). Dynamics of Hepatitis B Virus Resistance to Lamivudine. J. Virol. 80: 643-653 [Abstract] [Full Text]
Lim, S. G., Ng, T. M., Kung, N., Krastev, Z., Volfova, M., Husa, P., Lee, S. S., Chan, S., Shiffman, M. L., Washington, M. K., Rigney, A., Anderson, J., Mondou, E., Snow, A., Sorbel, J., Guan, R., Rousseau, F., for the Emtricitabine FTCB-301 Study Group, (2006). A Double-blind Placebo-Controlled Study of Emtricitabine in Chronic Hepatitis B. Arch Intern Med 166: 49-56 [Abstract] [Full Text]
Stephan, C., Berger, A., Carlebach, A., Lutz, T., Bickel, M., Klauke, S., Staszewski, S., Stuermer, M. (2005). Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 56: 1087-1093 [Abstract] [Full Text]
Guo, Y., Guo, H., Zhang, L., Xie, H., Zhao, X., Wang, F., Li, Z., Wang, Y., Ma, S., Tao, J., Wang, W., Zhou, Y., Yang, W., Cheng, J. (2005). Genomic Analysis of Anti-Hepatitis B Virus (HBV) Activity by Small Interfering RNA and Lamivudine in Stable HBV-Producing Cells. J. Virol. 79: 14392-14403 [Abstract] [Full Text]
Ou, Z.-Y., Liu, N., Chen, C.-J., Cheng, G., He, Y.-S. (2005). Rapid and Accurate Genotyping of YMDD Motif Variants in the Hepatitis B Virus Genome by an Improved Reverse Dot Blot Method. J. Clin. Microbiol. 43: 5685-5689 [Abstract] [Full Text]
Hui, C-K, Cheung, W W W, Au, W-Y, Lie, A K W, Zhang, H-Y, Yueng, Y-H, Wong, B C Y, Leung, N, Kwong, Y-L, Liang, R, Lau, G K K (2005). Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 54: 1597-1603 [Abstract] [Full Text]
Casey, J., Cote, P. J., Toshkov, I. A., Chu, C. K., Gerin, J. L., Hornbuckle, W. E., Tennant, B. C., Korba, B. E. (2005). Clevudine Inhibits Hepatitis Delta Virus Viremia: a Pilot Study of Chronically Infected Woodchucks. Antimicrob. Agents Chemother. 49: 4396-4399 [Abstract] [Full Text]
Pai, S. B., Bozdayi, A. M., Pai, R. B., Beker, T., Sarioglu, M., Turkyilmaz, A. R., Grier, J., Yurdaydin, C., Schinazi, R. F. (2005). Emergence of a Novel Mutation in the FLLA Region of Hepatitis B Virus during Lamivudine Therapy. Antimicrob. Agents Chemother. 49: 2618-2624 [Abstract] [Full Text]
Erhardt, A, Blondin, D, Hauck, K, Sagir, A, Kohnle, T, Heintges, T, Haussinger, D (2005). Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 54: 1009-1013 [Abstract] [Full Text]
Lau, G. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., Chang, W. Y., Berg, T., Flisiak, R., McCloud, P., Pluck, N., the Peginterferon Alfa-2a HBeAg-Positive Chronic H, (2005). Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. NEJM 352: 2682-2695 [Abstract] [Full Text]
Kanwal, F., Gralnek, I. M., Martin, P., Dulai, G. S., Farid, M., Spiegel, B. M.R. (2005). Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis. ANN INTERN MED 142: 821-831 [Abstract] [Full Text]
Chan, C., Abu-Raddad, E., Golor, G., Watanabe, H., Sasaki, A., Yeo, K. P., Soon, D., Sinha, V. P., Flanagan, S. D., He, M. M., Wise, S. D. (2005). Clinical Pharmacokinetics of Alamifovir and Its Metabolites. Antimicrob. Agents Chemother. 49: 1813-1822 [Abstract] [Full Text]
Chan, H. L.-Y., Leung, N. W.-Y., Hui, A. Y., Wong, V. W.-S., Liew, C.-T., Chim, A. M.-L., Chan, F. K.-L., Hung, L. C.-T., Lee, Y.-T., Tam, J. S.-L., Lam, C. W.-K., Sung, J. J.-Y. (2005). A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-{alpha}2b and Lamivudine with Lamivudine Alone. ANN INTERN MED 142: 240-250 [Abstract] [Full Text]
Carotenuto, P., van Riel, D., Artsen, A., Bruijns, S., Uytdehaag, F. G., Laman, J. D., van Nunen, A. B., Zondervan, P. E., De Man, R. A., Osterhaus, A. D., Pontesilli, O. (2005). Antiviral Treatment with Alpha Interferon Up-Regulates CD14 on Liver Macrophages and Its Soluble Form in Patients with Chronic Hepatitis B. Antimicrob. Agents Chemother. 49: 590-599 [Abstract] [Full Text]
Konnick, E. Q., Erali, M., Ashwood, E. R., Hillyard, D. R. (2005). Evaluation of the COBAS Amplicor HBV Monitor Assay and Comparison with the Ultrasensitive HBV Hybrid Capture 2 Assay for Quantification of Hepatitis B Virus DNA. J. Clin. Microbiol. 43: 596-603 [Abstract] [Full Text]
Lin, C-L, Tsai, S-L, Lee, T-H, Chien, R-N, Liao, S-K, Liaw, Y-F (2005). High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B. Gut 54: 152-161 [Abstract] [Full Text]
Aggarwal, R., Ranjan, P. (2004). Preventing and treating hepatitis B infection. BMJ 329: 1080-1086 [Full Text]
Mizukoshi, E., Sidney, J., Livingston, B., Ghany, M., Hoofnagle, J. H., Sette, A., Rehermann, B. (2004). Cellular Immune Responses to the Hepatitis B Virus Polymerase. J. Immunol. 173: 5863-5871 [Abstract] [Full Text]
Liaw, Y. F., Sung, J. J.Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., Dixon, J. S., Gray, D. F., Sabbat, J., the Cirrhosis Asian Lamivudine Multicentre Study G, (2004). Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease. NEJM 351: 1521-1531 [Abstract] [Full Text]
Yuen, M.-F., Yuan, H.-J., Sablon, E., Wong, D. K.-H., Chan, A. O.-O., Wong, B. C.-Y., Lai, C.-L. (2004). Long-Term Follow-Up Study of Chinese Patients with YMDD Mutations: Significance of Hepatitis B Virus Genotypes and Characteristics of Biochemical Flares. J. Clin. Microbiol. 42: 3932-3936 [Abstract] [Full Text]
Walters, K.-A., Joyce, M. A., Addison, W. R., Fischer, K. P., Tyrrell, D. L. J. (2004). Superinfection Exclusion in Duck Hepatitis B Virus Infection Is Mediated by the Large Surface Antigen. J. Virol. 78: 7925-7937 [Abstract] [Full Text]
Jacquard, A. C., Nassal, M., Pichoud, C., Ren, S., Schultz, U., Guerret, S., Chevallier, M., Werle, B., Peyrol, S., Jamard, C., Rimsky, L. T., Trepo, C., Zoulim, F. (2004). Effect of a Combination of Clevudine and Emtricitabine with Adenovirus-Mediated Delivery of Gamma Interferon in the Woodchuck Model of Hepatitis B Virus Infection. Antimicrob. Agents Chemother. 48: 2683-2692 [Abstract] [Full Text]
D'Souza, R., Foster, G. R (2004). Diagnosis and treatment of chronic hepatitis B. JRSM 97: 318-321 [Full Text]
Sawabe, T., Uenotsuchi, T., Imafuku, S., Kohno, H., Arima, J., Horiuchi, T. (2004). Remission of Hepatitis B Virus-Related Vasculitis with Lamivudine. ANN INTERN MED 140: 672-673 [Full Text]
Rivkin, A. M (2004). Adefovir Dipivoxil in the Treatment of Chronic Hepatitis B. The Annals of Pharmacotherapy 38: 625-633 [Abstract] [Full Text]
Yeo, W., Chan, P. K.S., Ho, W. M., Zee, B., Lam, K. C., Lei, K. I.K., Chan, A. T.C., Mok, T. S.K., Lee, J. J., Leung, T. W.T., Zhong, S., Johnson, P. J. (2004). Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy. JCO 22: 927-934 [Abstract] [Full Text]
Hannon, H., Isnard Bagnis, C., Benhamou, Y., Beaufils, H., Sullivan, M., Brosgart, C., Izzedine, H., Poynard, T., Deray, G. (2004). The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. Nephrol Dial Transplant 19: 386-390 [Abstract] [Full Text]
Dai, C-Y, Yu, M-L, Chen, S-C, Lin, Z-Y, Hsieh, M-Y, Wang, L-Y, Tsai, J-F, Chuang, W-L, Chang, W-Y (2004). Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan. J. Clin. Pathol. 57: 141-145 [Abstract] [Full Text]
Krishnan, P., Gullen, E. A., Lam, W., Dutschman, G. E., Grill, S. P., Cheng, Y.-c. (2003). Novel Role of 3-Phosphoglycerate Kinase, a Glycolytic Enzyme, in the Activation of L-Nucleoside Analogs, a New Class of Anticancer and Antiviral Agents. J. Biol. Chem. 278: 36726-36732 [Abstract] [Full Text]
Seigneres, B., Martin, P., Werle, B., Schorr, O., Jamard, C., Rimsky, L., Trepo, C., Zoulim, F. (2003). Effects of Pyrimidine and Purine Analog Combinations in the Duck Hepatitis B Virus Infection Model. Antimicrob. Agents Chemother. 47: 1842-1852 [Abstract] [Full Text]
Walters, K.-A., Tipples, G. A., Allen, M. I., Condreay, L. D., Addison, W. R., Tyrrell, L. (2003). Generation of Stable Cell Lines Expressing Lamivudine-Resistant Hepatitis B Virus for Antiviral-Compound Screening. Antimicrob. Agents Chemother. 47: 1936-1942 [Abstract] [Full Text]
Carman, W. F., Cameron, S. O. (2003). What should be done about hepatitis-B-infected health-care workers?. J Med Microbiol 52: 371-372 [Full Text]
Ho, S. K.N., Yam, W.-C., Leung, E. T.K., Wong, L.-P., Leung, J. K.H., Lai, K.-N., Chan, T.-M. (2003). Rapid quantification of hepatitis B virus DNA by real-time PCR using fluorescent hybridization probes. J Med Microbiol 52: 397-402 [Abstract] [Full Text]
Karayiannis, P. (2003). Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 51: 761-785 [Abstract] [Full Text]
Thabut, D, Ratziu, V, Bernard-Chabert, B, Poynard, T, Benhamou, Y, Thibault, V (2003). Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure. Gut 52: 614-614 [Full Text]
Yuen, M-F, Yuan, H-J, Hui, C-K, Wong, D K-H, Wong, W-M, Chan, A O-O, Wong, B C-Y, Lai, C-L (2003). A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 52: 416-419 [Abstract] [Full Text]
van Nunen, A B, Hansen, B E, Suh, D J, Lohr, H F, Chemello, L, Fontaine, H, Heathcote, J, Song, B C, Janssen, H L A, de Man, R A, Schalm, S W (2003). Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52: 420-424 [Abstract] [Full Text]
Yuen, M.-F., Lai, C.-L. (2003). Current and future antiviral agents for chronic hepatitis B. J Antimicrob Chemother 51: 481-485 [Full Text]
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., Fry, J., Brosgart, C. L., the Adefovir Dipivoxil 437 Study Group, (2003). Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B. NEJM 348: 808-816 [Abstract] [Full Text]
Mailliard, M. E., Gollan, J. L. (2003). Suppressing Hepatitis B without Resistance -- So Far, So Good. NEJM 348: 848-850 [Full Text]
Abdelhamed, A. M., Kelley, C. M., Miller, T. G., Furman, P. A., Cable, E. E., Isom, H. C. (2003). Comparison of Anti-Hepatitis B Virus Activities of Lamivudine and Clevudine by a Quantitative Assay. Antimicrob. Agents Chemother. 47: 324-336 [Abstract] [Full Text]
Lok, A. S. F., Zoulim, F., Locarnini, S., Mangia, A., Niro, G., Decraemer, H., Maertens, G., Hulstaert, F., De Vreese, K., Sablon, E. (2002). Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay. J. Clin. Microbiol. 40: 3729-3734 [Abstract] [Full Text]
Lim, S G, Wai, C T, Rajnakova, A, Kajiji, T, Guan, R (2002). Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 51: 597-599 [Abstract] [Full Text]
Yu, M.-W., Chang, H.-C., Chen, P.-J., Liu, C.-J., Liaw, Y.-F., Lin, S.-M., Lee, S.-D., Lin, S.-C., Lin, C.-L., Chen, C.-J. (2002). Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol 31: 1008-1015 [Abstract] [Full Text]
Kamiya, N., Kubota, A., Iwase, Y., Sekiya, K., Ubasawa, M., Yuasa, S. (2002). Antiviral Activities of MCC-478, a Novel and Specific Inhibitor of Hepatitis B Virus. Antimicrob. Agents Chemother. 46: 2872-2877 [Abstract] [Full Text]
Ono-Nita, S. K., Kato, N., Shiratori, Y., Carrilho, F. J., Omata, M. (2002). Novel Nucleoside Analogue MCC-478 (LY582563) Is Effective against Wild-Type or Lamivudine-Resistant Hepatitis B Virus. Antimicrob. Agents Chemother. 46: 2602-2605 [Abstract] [Full Text]
NIESTERS, H. G. M., DE MAN, R. A., PAS, S. D., FRIES, E., OSTERHAUS, A. D. M. E. (2002). Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol 51: 695-699 [Abstract] [Full Text]
Shibolet, O., Ilan, Y., Gillis, S., Hubert, A., Shouval, D., Safadi, R. (2002). Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100: 391-396 [Abstract] [Full Text]
Gish, R. G., Leung, N. W. Y., Wright, T. L., Trinh, H., Lang, W., Kessler, H. A., Fang, L., Wang, L. H., Delehanty, J., Rigney, A., Mondou, E., Snow, A., Rousseau, F. (2002). Dose Range Study of Pharmacokinetics, Safety, and Preliminary Antiviral Activity of Emtricitabine in Adults with Hepatitis B Virus Infection. Antimicrob. Agents Chemother. 46: 1734-1740 [Abstract] [Full Text]
Jonas, M. M., Kelley, D. A., Mizerski, J., Badia, I. B., Areias, J. A., Schwarz, K. B., Little, N. R., Greensmith, M. J., Gardner, S. D., Bell, M. S., Sokal, E. M., the International Pediatric Lamivudine Investigato, (2002). Clinical Trial of Lamivudine in Children with Chronic Hepatitis B. NEJM 346: 1706-1713 [Abstract] [Full Text]
Lau, G. K. K., Leung, Y.-h., Fong, D. Y. T., Au, W.-y., Kwong, Y.-l., Lie, A., Hou, J.-l., Wen, Y.-m., Nanj, A., Liang, R. (2002). High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99: 2324-2330 [Abstract] [Full Text]
Delmas, J., Schorr, O., Jamard, C., Gibbs, C., Trepo, C., Hantz, O., Zoulim, F. (2002). Inhibitory Effect of Adefovir on Viral DNA Synthesis and Covalently Closed Circular DNA Formation in Duck Hepatitis B Virus-Infected Hepatocytes In Vivo and In Vitro. Antimicrob. Agents Chemother. 46: 425-433 [Abstract] [Full Text]
Mutimer, D, Feraz-Neto, B H, Harrison, R, O'Donnell, K, Shaw, J, Cane, P, Pillay, D (2001). Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 49: 860-863 [Abstract] [Full Text]
Gow, P. J, Mutimer, D. (2001). Regular review: Treatment of chronic hepatitis. BMJ 323: 1164-1167 [Full Text]
McMahon, B. J., Holck, P., Bulkow, L., Snowball, M. (2001). Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus. ANN INTERN MED 135: 759-768 [Abstract] [Full Text]
Chin, R., Shaw, T., Torresi, J., Sozzi, V., Trautwein, C., Bock, T., Manns, M., Isom, H., Furman, P., Locarnini, S. (2001). In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to ({-})-{beta}-D-2,6-Diaminopurine Dioxolane and 2'-Fluoro-5-Methyl-{beta}-L-Arabinofuranosyluracil. Antimicrob. Agents Chemother. 45: 2495-2501 [Abstract] [Full Text]
Lee, J.-Y., Culvenor, J. G., Angus, P., Smallwood, R., Nicoll, A., Locarnini, S. (2001). Duck Hepatitis B Virus Replication in Primary Bile Duct Epithelial Cells. J. Virol. 75: 7651-7661 [Abstract] [Full Text]
Walsh, K, Alexander, G J M (2001). Update on chronic viral hepatitis. Postgrad. Med. J. 77: 498-505 [Abstract] [Full Text]
Malanchere-Bres, E., Payette, P. J., Mancini, M., Tiollais, P., Davis, H. L., Michel, M.-L. (2001). CpG Oligodeoxynucleotides with Hepatitis B Surface Antigen (HBsAg) for Vaccination in HBsAg-Transgenic Mice. J. Virol. 75: 6482-6491 [Abstract] [Full Text]
Delaney, W. E. IV, Edwards, R., Colledge, D., Shaw, T., Torresi, J., Miller, T. G., Isom, H. C., Bock, C. T., Manns, M. P., Trautwein, C., Locarnini, S. (2001). Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus. Antimicrob. Agents Chemother. 45: 1705-1713 [Abstract] [Full Text]
Das, K., Xiong, X., Yang, H., Westland, C. E., Gibbs, C. S., Sarafianos, S. G., Arnold, E. (2001). Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC). J. Virol. 75: 4771-4779 [Abstract] [Full Text]
Aberle, S. W., Kletzmayr, J., Watschinger, B., Schmied, B., Vetter, N., Puchhammer-Stöckl, E. (2001). Comparison of Sequence Analysis and the INNO-LiPA HBV DR Line Probe Assay for Detection of Lamivudine-Resistant Hepatitis B Virus Strains in Patients under Various Clinical Conditions. J. Clin. Microbiol. 39: 1972-1974 [Abstract] [Full Text]
Le Guerhier, F., Pichoud, C., Jamard, C., Guerret, S., Chevallier, M., Peyrol, S., Hantz, O., King, I., Trépo, C., Cheng, Y.-C., Zoulim, F. (2001). Antiviral Activity of {beta}-L-2',3'-Dideoxy-2',3'-Didehydro-5-Fluorocytidine in Woodchucks Chronically Infected with Woodchuck Hepatitis Virus. Antimicrob. Agents Chemother. 45: 1065-1077 [Abstract] [Full Text]
Whalley, S. A., Brown, D., Teo, C. G., Dusheiko, G. M., Saunders, N. A. (2001). Monitoring the Emergence of Hepatitis B Virus Polymerase Gene Variants during Lamivudine Therapy Using the LightCycler. J. Clin. Microbiol. 39: 1456-1459 [Abstract] [Full Text]
Bryant, M. L., Bridges, E. G., Placidi, L., Faraj, A., Loi, A.-G., Pierra, C., Dukhan, D., Gosselin, G., Imbach, J.-L., Hernandez, B., Juodawlkis, A., Tennant, B., Korba, B., Cote, P., Marion, P., Cretton-Scott, E., Schinazi, R. F., Sommadossi, J.-P. (2001). Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection. Antimicrob. Agents Chemother. 45: 229-235 [Abstract] [Full Text]
Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., Seeff, L. B. (2000). Diagnosis and Monitoring of Hepatic Injury. II. Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Monitoring. Clin. Chem. 46: 2050-2068 [Abstract] [Full Text]
Reshef, R., Sbeit, W., Tur-Kaspa, R. (2000). Lamivudine in the Treatment of Acute Hepatitis B. NEJM 343: 1123-1124 [Full Text]
KASISKE, B. L., VAZQUEZ, M. A., HARMON, W. E., BROWN, R. S., DANOVITCH, G. M., GASTON, R. S., ROTH, D., SCANDLING, J. D. JR., SINGER, G. G. (2000). Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. J. Am. Soc. Nephrol. 11: S1-S86 [Abstract] [Full Text]
Chan, H. L. Y., Leung, N. W. Y., Lau, T. C. M., Wong, M. L., Sung, J. J. Y. (2000). Comparison of Three Different Sensitive Assays for Hepatitis B Virus DNA in Monitoring of Responses to Antiviral Therapy. J. Clin. Microbiol. 38: 3205-3208 [Abstract] [Full Text]
Lau, G. K. K., Lie, A. K. W., Kwong, Y. L., Lee, C. K., Hou, J., Lau, Y. L., Lim, W. L., Liang, R. (2000). A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood 96: 452-458 [Abstract] [Full Text]
Chen, W. N., Oon, C. J. (2000). Changes in the Antigenicity of a Hepatitis B Virus Mutant Stemming from Lamivudine Therapy. Antimicrob. Agents Chemother. 44: 1765-1765 [Full Text]
Malik, A. H., Lee, W. M. (2000). Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium. ANN INTERN MED 132: 723-731 [Abstract] [Full Text]
DOO, E, HOOFNAGLE, J H (2000). Combination therapy of hepatitis B. Gut 46: 450-451 [Full Text]
Schalm, S W, Heathcote, J, Cianciara, J, Farrell, G, Sherman, M, Willems, B, Dhillon, A, Moorat, A, Barber, J, Gray, D F, International Lamivudine Study Group, (2000). Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46: 562-568 [Abstract] [Full Text]
Schiff, E. R. (2000). Update in Hepatology. ANN INTERN MED 132: 460-466 [Full Text]
Colledge, D., Civitico, G., Locarnini, S., Shaw, T. (2000). In Vitro Antihepadnaviral Activities of Combinations of Penciclovir, Lamivudine, and Adefovir. Antimicrob. Agents Chemother. 44: 551-560 [Abstract] [Full Text]
Sokal, E. M., Roberts, E. A., Mieli-Vergani, G., McPhillips, P., Johnson, M., Barber, J., Dallow, N., Boxall, E., Kelly, D. (2000). A Dose Ranging Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of Lamivudine in Children and Adolescents with Chronic Hepatitis B. Antimicrob. Agents Chemother. 44: 590-597 [Abstract] [Full Text]
Poon, R. T.-P., Fan, S.-T., Lo, C.-M., Liu, C.-L., Ng, I. O.-L., Wong, J. (2000). Long-Term Prognosis After Resection of Hepatocellular Carcinoma Associated With Hepatitis B-Related Cirrhosis. JCO 18: 1094-1094 [Abstract] [Full Text]
Stuyver, L., Van Geyt, C., De Gendt, S., Van Reybroeck, G., Zoulim, F., Leroux-Roels, G., Rossau, R. (2000). Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy. J. Clin. Microbiol. 38: 702-707 [Abstract] [Full Text]
Le Guerhier, F., Pichoud, C., Guerret, S., Chevallier, M., Jamard, C., Hantz, O., Li, X.-Y., Chen, S.-H., King, I., Trépo, C., Cheng, Y.-C., Zoulim, F. (2000). Characterization of the Antiviral Effect of 2',3'-Dideoxy-2', 3'-Didehydro-beta -L-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model. Antimicrob. Agents Chemother. 44: 111-122 [Abstract] [Full Text]
Maclachlan, D., Battegay, M., Jacob, A. L., Tyndall, A. (2000). Successful treatment of hepatitis B-associated polyarteritis nodosa with a combination of lamivudine and conventional immunosuppressive therapy: a case report. Rheumatology (Oxford) 39: 106-108 [Full Text]
Utili, R., Zampino, R., Bellopede, P., Marracino, M., Ragone, E., Adinolfi, L. E., Ruggiero, G., Capasso, M., Indolfi, P., Casale, F., Martini, A., Di Tullio, M. T. (1999). Dual or Single Hepatitis B and C Virus Infections in Childhood Cancer Survivors: Long-Term Follow-Up and Effect of Interferon Treatment. Blood 94: 4046-4052 [Abstract] [Full Text]
Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H.-W. L., Goodman, Z., Crowther, L., Condreay, L. D., Woessner, M., Rubin, M., Brown, N. A., The U.S. Lamivudine Investigator Group, (1999). Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States. NEJM 341: 1256-1263 [Abstract] [Full Text]
Allen, M. I., Gauthier, J., DesLauriers, M., Bourne, E. J., Carrick, K. M., Baldanti, F., Ross, L. L., Lutz, M. W., Condreay, L. D. (1999). Two Sensitive PCR-Based Methods for Detection of Hepatitis B Virus Variants Associated with Reduced Susceptibility to Lamivudine. J. Clin. Microbiol. 37: 3338-3347 [Abstract] [Full Text]
Fan, S.-T., Ng, I. O. L., Poon, R. T. P., Lo, C.-M., Liu, C.-L., Wong, J. (1999). Hepatectomy for Hepatocellular Carcinoma: The Surgeon's Role in Long-term Survival. Arch Surg 134: 1124-1130 [Abstract] [Full Text]
Zuckerman, A J, Lavanchy, D (1999). Treatment options for chronic hepatitis. BMJ 319: 799-800 [Full Text]

Comments and questions? Please contact us.